Structure-guided rescaffolding of selective antagonists of BCL-X L
Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, potent BC
Koehler, Michael F. T.,Bergeron, Philippe,Choo, Edna F.,Lau, Kevin,Ndubaku, Chudi,Dudley, Danette,Gibbons, Paul,Sleebs, Brad E.,Rye, Carl S.,Nikolakopoulos, George,Bui, Chinh,Kulasegaram, Sanji,Kersten, Wilhelmus J. A.,Smith, Brian J.,Czabotar, Peter E.,Colman, Peter M.,Huang, David C. S.,Baell, Jonathan B.,Watson, Keith G.,Hasvold, Lisa,Tao, Zhi-Fu,Wang, Le,Souers, Andrew J.,Elmore, Steven W.,Flygare, John A.,Fairbrother, Wayne J.,Lessene, Guillaume
p. 662 - 667
(2014/07/07)
More Articles about upstream products of 1235034-75-9